"The transaction to license and acquire these products is a key first step in achieving our objective of building a leading specialty pharmaceutical company," added GTCR Principal, Dean Mihas. "The Actient management team led by Ed Fiorentino has an impressive track record of establishing and growing businesses and we're excited to be a partner in this transaction and are committed to providing the resources to further Actient's growth."

"I look forward to deepening Actient's partnership with GTCR through this initial transaction," noted Fiorentino. "GTCR's highly successful track record in branded pharmaceuticals and commitment to our growth will go a long way in helping us to achieve our vision of delivering clinically meaningful products to patients."

Kirkland & Ellis LLP and Hogan Lovells served as legal counsel to GTCR and Actient. Torreya Partners LLC served as financial advisor to GTCR and Actient. GE Capital and LBC Credit Partners provided the initial debt financing commitment in support of the acquisition. GTCR's investment in Actient to support the transaction was made from GTCR Fund IX, a private equity fund with $2.75 billion of committed capital.

SOURCE GTCR